Navigation Links
Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Date:10/11/2007

ing, which may provide greater mobility and improved sleep. More information about SBS is available on the website, http://www.shortbowel.com and http://www.glucagon.com.

About GATTEX

A potential first-in-class drug, GATTEX is a proprietary analog of naturally occurring human glucagon-like peptide 2 (GLP-2), a peptide secreted primarily in the distal intestine and involved in the regeneration and repair of the intestinal epithelium. A previous Phase 2 proof-of-concept clinical study in patients with SBS showed that daily subcutaneous injections of GATTEX resulted in significant regeneration of the intestinal lining and improved dietary absorption of nutrients and fluids. Once the company has completed its analysis of data from the Phase 3 SBS study, it expects to pursue a pre-NDA meeting with the U.S. Food and Drug Administration to discuss its potential plan for submitting a New Drug Application. NPS is also pursuing development of GATTEX as a possible treatment for chemotherapy-induced gastrointestinal mucositis in cancer patients and necrotizing enterocolitis in preterm infants.

Conference Call Information

A conference call will be held today at 9:00 a.m. EDT. To participate in the call, dial (866) 770-7125 with passcode 66355061. International callers may dial (617) 213-8066 using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's home page, http://www.npsp.com. A conference call replay will be available until October 22, 2007 at (888) 286-8010, or (617) 801-6888 for international callers, with passcode 47718436. The webcast will be available for replay and iPod(R) download for the same period.

Note: Statements made in this press release, which are not historical in nature, consti
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...ata Published in ,The Lancet, and Presented at ESC... Results from a new international,study, the GISSI... dose of,omega-3 acid ethyl esters reduced all cau...cular reasons in patients with chronic heart,failu...line version of ,The,Lancet, and were presented at...
(Date:9/4/2008)...NGHAM, Ala., Sept. 4 /- Southern Rese...nstitutes of Health (NIH) has selected,the organiz... Libraries,Probe Production Center Network (MLPCN)... is part of the Molecular Libraries Program which ...tific knowledge of the human,genome and validate f...
(Date:9/4/2008)...H, Switzerland, September 4 /- Axenti...al to assess the safety and tolerability,of a new ...e pulmonary,infection in cystic fibrosis patients....utic agent to be delivered directly to the site of...e the effects of two,different doses of the new dr...
(Date:9/4/2008)...cohort demonstrates potent antiviral activity and ...file -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-Fir...IDIX ), a biopharmaceutical company engaged,in the...ent of human viral,and other infectious diseases, ...-concept study evaluating IDX899, a non-nucleoside...
Breaking Medicine Technology:New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Sacramento Chiropractor Takes Aim at Reducing Car Accident Injuries 18587 1Sacramento Chiropractor Takes Aim at Reducing Car Accident Injuries 18587 2Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 18584 1Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 18584 2Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 18584 3Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 18584 4Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 18584 5Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 18584 6Tepper School Team Takes Top Honors at Global Moot Corp 28R 29 Competition 5154 1Tepper School Team Takes Top Honors at Global Moot Corp 28R 29 Competition 5154 2Naturally occuring protein may be effective in limiting heart attack injury and restoring function 18582 1Naturally occuring protein may be effective in limiting heart attack injury and restoring function 18582 2
...NEVA, Switzerland, April 27, 2007 –,Merck Se...rmaceuticals S.p.A. (SWX: NWRN) announced today th...nt the results of the first,Phase III trial of saf...nists (DA) in early Parkinson’s disease (PD)...h Annual Meeting,to be held in Boston from 28 Apri...
...STER, Minn., April 30. 2007-- Scientific evidence,...resence of,nanosized particles -- so small that so...live and, if so, play a viable role in,causing dis...owing the presence of,nanoparticles near plaque-fi... that nanoparticles potentially represent a,previo...
Other Medicine Technology:Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4Evidence of Nanoparticles Found in Plaque-Filled Arteries 2
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...on is putting his best foot forward with respect t...ions are rife for the parties’ annual spring// con...terated that curtailing health problems like obesi...and the risk of sexually transmitted diseases is v...
...ch age of modern medicine, could it be possible to...ugh the power //of meditation? According to a stud...technique can significantly reduce the severity of...lts of this study indicate that transcendental med...
... insulin therapy on the medical-surgical wards res...dividualized management// in patients with diabeti...may be possible. “This is the first randomized ... subcutaneous insulin protocol on medical-surgical...
...c, which is present in every part of the body, cou...study that could help// in the development of new ...ribute to the formation of plaques in the brains o... disease. It is also vital for the healthy working...
Other Medicine News:Health News:Transcendental Meditation Can Help 2Health News:New Research May Pave the Way for Shorter Hospital Stays for Diabetes Patients 2
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field.
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
Handheld Digital Retinal Camera
Medicine Products: